Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. A. WILCOX

Lentivirus-Mediated Platelet Gene Therapy of Murine Hemophilia a With Pre-Existing Anti-Factor VIII Immunity

Journal of Thrombosis and Haemostasis

Medicine

Hematology

2012

English

Related publications

Immune Tolerance Induced by Platelet-Targeted Factor VIII Gene Therapy in Hemophilia a Mice Is CD4 T Cell-Mediated

Journal of Thrombosis and Haemostasis

Medicine

Hematology

2017

English

Platelet-Targeted Gene Therapy for Hemophilia

Molecular Therapy - Methods and Clinical Development

English

244. Factor VIII Immunogenicity Is a Barrier to AAV Gene Therapy for Hemophilia A

English

Factor VIII Associated With Lipidic Nanoparticles Retains Efficacy in the Presence of Anti-Factor VIII Antibodies in Hemophilia a Mice

Biopharmaceutics and Drug Disposition

Medicine

Pharmacology

Pharmaceutical Science

2016

English

Creating a DDAVP Releasable Pool of Factor VIII: Its Impact on the Gene Therapy of Hemophilia a † 786

English

Postpartum Acquired Hemophilia Factor VIII �nhibitors and Response to Therapy

Turkish Journal of Haematology

Hematology

2012

English

Pre-Existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy

Human gene therapy methods

English

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A

English

Expression of Human Coagulation Factor VIII in Adipocytes Transduced With the Simian Immunodeficiency Virus agmTYO1-based Vector for Hemophilia a Gene Therapy

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. A. WILCOX

Lentivirus-Mediated Platelet Gene Therapy of Murine Hemophilia a With Pre-Existing Anti-Factor VIII Immunity

Related publications

Immune Tolerance Induced by Platelet-Targeted Factor VIII Gene Therapy in Hemophilia a Mice Is CD4 T Cell-Mediated

Platelet-Targeted Gene Therapy for Hemophilia

244. Factor VIII Immunogenicity Is a Barrier to AAV Gene Therapy for Hemophilia A

Factor VIII Associated With Lipidic Nanoparticles Retains Efficacy in the Presence of Anti-Factor VIII Antibodies in Hemophilia a Mice

Creating a DDAVP Releasable Pool of Factor VIII: Its Impact on the Gene Therapy of Hemophilia a † 786

Postpartum Acquired Hemophilia Factor VIII �nhibitors and Response to Therapy

Pre-Existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A

Expression of Human Coagulation Factor VIII in Adipocytes Transduced With the Simian Immunodeficiency Virus agmTYO1-based Vector for Hemophilia a Gene Therapy